RE:RE:Anticipation of the UHN ERB Monday ...If my percent calculator is working correctly, those 90 programs are 20% of 450 R&D programs total, meaning Novartis still has 360 programs to throw money at, so no big deal really.
They should cut 20% more and buy Theralase.
LaserStock29 wrote: Novartis cuts 20% of R&D programs “The sadness about these 90 projects is there’s some great science there,” Bradner said. “These are not bad ideas. Many of them have momentum, but they either are not likely to be transformative for patients, or are ill-suited to the focused business ambitions of Novartis.”
Well I can think of good science with great momentum is transformative for patients and is low cost and high effectiveness as bencro pointed out a while back with Novartis's R&D guy.
seems every deal outthere is for Car-T and Gene therapies...
If u carry the decimal point adjust for mice inflation, account for square root of the expoential power divided by deflation..
you get .30 cents....
darn.
lol